According to Clinical Trials Registry Platform, a platform that gathers data from clinical trials across the planet, more than 2,700 studies involving treatments against covid-19 have been recorded since the beginning of the pandemic in 2020, of which 1,400 are looking for volunteers in the moment or have already gone through this stage.
One of the ongoing trials is the serum developed by the Butantan Institute, which recently received authorization from the National Health Surveillance Agency (Anvisa) to start testing on humans.
The tests continue at an accelerated pace in the laboratories.Source: Unsplash
In addition to it, we highlight below other experimental treatments against covid-19 that have advanced in recent weeks and may be essential to reduce the number of deaths in the near future, if they are definitively approved.
The product, which consists of an injectable liquid composed of antibodies against Sars-CoV-2, aims to curb the worsening of the disease in those infected, especially protecting the lung, as demonstrated by tests carried out on animals, considered extremely effective by the institute.
Butantan’s covid-19 serum can now begin testing.Source: Unsplash
The reduction of viral load in patients and the fight against different variants of the coronavirus were also noticed in the first stages. With the start of tests on humans, it will be possible to check the safety, the ideal dosage and its effectiveness in a large number of people.
Roche anticovid cocktail
Developed by the pharmaceutical company Roche, the cocktail is in phase 3, in which it will be possible to test its effectiveness. Administered by intravenous application, it combines the substances casirivimab and imdevimab, which were able to reduce by 70% the risk of hospitalization and death in tests performed on people with the possibility of worsening the condition.
It has intravenous application.Source: Pixabay
Made with monoclonal antibodies, reproduced in the laboratory from antibodies taken from recovered patients, the cocktail also reduced the duration of symptoms from 14 to 10 days, with side effects in only 1% of patients.
Created by Merck Sharp & Dome (MSD) in partnership with Ridgeback Biotherapeutics, Molnupiravir is an oral antiviral that works by reducing viral load after the fifth day of treatment in outpatients, according to the laboratories. The adverse effects in the initial experiments were considered “irrelevant”.
Antiviral to Merck and to Ridgeback.Source: Unsplash
It works by inhibiting the replication of RNA viruses, as is the case of the cause of covid-19, and has also been shown to be effective in laboratory studies against MERS-CoV and Sars-CoV-1, related to the appearance of symptoms of the syndrome respiratory.
Antiviral da Pfizer
Also administered orally, shortly after the appearance of the first symptoms, the antiviral developed by Pfizer has started to be tested in humans now. But the in vitro experiments resulted in a potent action against Sars-CoV-2, according to the company.
Pfizer is also developing an antiviral, in addition to creating a vaccine.Source: Unsplash
This medicine, called PF-07321332, is a protease inhibitor, an enzyme that causes the virus to multiply in the body. By acting in the early stages of the infection, it prevents the pathogen from replicating in the cells, and can help prevent the development of more severe conditions.
Get the latest news delivered to your inbox
Follow us on social media networks